TRML: Tourmaline Bio Inc Company Value to Net Income
Tourmaline Bio, Inc. (TRML) collaborates with scientific centers to develop therapies for rare immune pathologies. Strong patent protection for antibodies in untapped niches guarantees high profitability. However, success depends on a single asset and the availability of capital. The P/E ratio trend helps assess the company's market value, where -14.10 shows the current value of the metric.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_TRML_-_Tourmaline-Bio-Inc._-_PE-Multiple "TRML: Tourmaline Bio, Inc. Business Payback Period 02/21/2024 - 11/08/2025 | 👁️GURU.Markets👁️")
Analytical breakdowns for Tourmaline Corp (TRML)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
TRML - Company Net Income|Expected Net Profit Tourmaline Bio, Inc.|TRML - Price to Earnings Ratio|Forward P/E Multiple Tourmaline Bio Inc|TRML - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Tourmaline Bio, Inc.|TRML - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Tourmaline Bio|TRML - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth tourmalinebio.com|TRML - Earnings per share growth in current year|Net earnings per share growth forecast for next year Tourmaline Bio, Inc.
Comprehensive company analysis:tourmalinebio.com TRML
Tourmaline Bio, Inc. (TRML) specialization in unique therapies for immune pathologies drives a high business valuation premium, which is reflected in the ratio of market capitalization to net income. This coefficient measures the investment payback period, allowing for an assessment of the current balance between market expectations and actual financial results via the company's average P/E.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|ABCL: Price to Earnings Ratio|Precigen Corp - Market Price to Net Income Ratio|Pharming Group N.V. (PHAR) - Price to Earnings Ratio|Market Cap to Earnings nektar.com (NKTR)|Price to Earnings Ratio UPB|P/E Multiple Zenas Bio|Price to Earnings Ratio Immunome Corp (IMNM)|GOSS (Gossamer Bio Corp.) - Company Value to Net Income|Price to Earnings Ratio KalVista Pharmaceuticals KALV|SEPN - Price to Earnings Ratio|Pieris Pharmaceuticals, Inc. - P/E Multiple|SVRA - P/E Multiple|Rigel Pharmaceuticals Inc (RIGL) - Price to Earnings Ratio|ANAB (AnaptysBio Inc.) - Price to Earnings Ratio|ATXS (Astria Therapeutics) - P/E Multiple|engene.com (ENGN) - Business Payback Period|Price to Earnings Ratio RAPT Therapeutics (RAPT)|aerovatetx.com - Price to Earnings Multiple|P/E Multiple ACRS (Aclaris)|Kyverna Therapeutics, Inc (KYTX) - Market Cap to Earnings|TLSA: Price to Earnings Ratio|Company Value to Net Income CABA (cabalettabio.com)|VTYX: P/E Multiple|THTX (Theratechnologies, Inc.) - Price to Earnings Ratio|AVTX (Avalo Therapeutics Inc.) - P/E Multiple|Eledon Pharmaceuticals, Inc (ELDN) - Business Payback Period|Price to Earnings Ratio Agenus (AGEN)|CLYM - Market Cap to Earnings|Zura Bio - Price to Earnings Ratio|Company Value to Net Income ATYR|Adagene Corp - P/E Multiple|Business Payback Period ImageneBio Inc IMA|shattucklabs.com (STTK) - Price to Earnings Ratio|Price to Earnings Multiple EQ|CNTB (Connect Biopharma Holdings) - P/E Multiple|Price to Earnings Ratio Immunic Inc (IMUX)|Price to Earnings Ratio ATRA (Atara Biotherapeutics)|Business Payback Period inflarx.de|X4 Pharmaceuticals - Price to Earnings Ratio|Market Price to Net Income Ratio ACET (Adicet Bio Inc.)|CELU - Price to Earnings Ratio|Company Value to Net Income INMB (INmune Bio Inc)|Barinthus Bio (BRNS) - Price to Earnings Ratio|Price to Earnings Ratio Kezar Life Sciences Inc|Price to Earnings Ratio SAB Biotherapeutics|Price to Earnings Ratio AKTX|Price to Earnings Ratio Enlivex Therapeutics (ENLV)|QTTB: Market Cap to Net Income|P/E Multiple GOVX (GeoVax Labs Inc)|Company Value to Net Income EDSA|iBio, Inc. - P/E Multiple|CARM - P/E Multiple|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Biotherapeutics, Inc. - Company Value to Net Income|Price to Earnings Ratio HCW Biologics, Inc.|Price to Earnings Ratio Aptevo (APVO)|P/E Multiple AIM|P/E Multiple aditxt.com (ADTX)|GRI Bio - Price to Earnings Ratio|Company Value to Net Income XRTX|ReShape Lifesciences - P/E Multiple|Business Payback Period Revelation Biosciences Corp REVB|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|Price to Earnings Ratio scinai.com|Price to Earnings Ratio CalciMedica Inc|Price to Earnings Ratio Affimed Therapeutics (AFMD)|Price to Earnings Ratio ALLK (Allakos Inc.)|P/E Multiple hookipapharma.com (HOOK)|Price to Earnings Ratio IGM Biosciences IGMS|ITOS: Price to Earnings Multiple|Ocean Biomedical - P/E Multiple|Market Cap to Earnings TC BioPharm (Holdings) Plc|THRD (Third Harmonic Bio, Inc) - Price to Earnings Ratio
